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Abstract
Background: This small, pilot study evaluated the impact of treatment with a natural multi-mineral
supplement from seaweed (Aquamin) on walking distance, pain and joint mobility in subjects with
moderate to severe osteoarthritis of the knee.
Methods: Subjects (n = 70) with moderate to severe osteoarthritis of the knee were randomized
to four double-blinded treatments for 12 weeks: (a) Glucosamine sulfate (1500 mg/d); (b) Aquamin
(2400 mg/d); (c) Combined treatment composed of Glucosamine sulfate (1500 mg/d) plus Aquamin
(2400 mg/d) and (d) Placebo. Primary outcome measures were WOMAC scores and 6 Minute
Walking Distances (6 MWD). Laboratory based blood tests were used as safety measures.
Results: Fifty subjects completed the study and analysis of the data showed significant differences
between the groups for changes in WOMAC pain scores over time (p = 0.009 ANCOVA);
however, these data must be reviewed with caution since significant differences were found
between the groups at baseline for WOMAC pain and stiffness scores (p = 0.0039 and p = 0.013,
respectively, ANOVA). Only the Aquamin and Glucosamine groups demonstrated significant
improvements in symptoms over the course of the study. The combination group (like the placebo
group) did not show any significant improvements in OA symptoms in this trial. Within group
analysis demonstrated significant improvements over time on treatment for the WOMAC pain,
activity, composite and stiffness (Aquamin only) scores as well as the 6 minute walking distances
for subjects in the Aquamin and Glucosamine treatment groups. The Aquamin and Glucosamine
groups walked 101 feet (+7%) and 56 feet (+3.5%) extra respectively. All treatments were well
tolerated and the adverse events profiles were not significantly different between the groups.
Conclusion: This small preliminary study suggested that a multi mineral supplement (Aquamin)
may reduce the pain and stiffness of osteoarthritis of the knee over 12 weeks of treatment and
warrants further study.
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Introduction
Osteoarthritis (OA), also called degenerative joint disease,
is a slow destructive process of the joint affecting millions
of people worldwide. Although the exact biochemical
cause of OA remains unknown, the process usually begins
when the joint structures are abnormal or the stress placed
on the joint surfaces is unusually high. The secondary
inflammation due to progressive articular destruction
appears to be localized to the particular joint being
affected. Current anti-inflammatory treatments for OA
while providing some relief from symptoms are subopti-
mal and the side effects associated with these treatments;
in particular the COX-2 specific NSAID's are becoming
increasingly recognized [1,2]. As a result of this, use of
alternative treatments and complementary medicines are
gaining popularity in the United States among OA suffer-
ers.
Glucosamine, a structural component of cartilage, is rec-
ognized as a nutritional supplement by the US FDA but as
a pharmaceutical product in most European and Scandan-
avian countries as well as some Asian and Latin American
Countries. Glucosamine has been the subject of many tri-
als [3,4] and is used worldwide as an "alternative" treat-
ment for OA although the extent to which it may provide
relief to the symptoms of OA is still unclear. The recent
NIH funded Glucosamine/Chondroitin Arthritis Inter-
vention Trial (GAIT) tested the efficacy of glucosamine in
providing relief for subjects with symptomatic knee oste-
oarthritis [5]. In this multi-centre study, glucosamine
hydrochloride was tested either alone or in combination
with chondroitin sulfate, a gycosaminoglycan that is also
a structural component of cartilage and a popular alterna-
tive therapy for OA. In this study, the overall group of sub-
jects failed to demonstrate an improvement in symptoms
for both the individual and combined treatments possibly
as a result of the large (60%) placebo effect observed.
Some benefit was observed in a subset of subjects with
moderate to severe knee osteoarthritis suggesting that the
benefits of these nutraceuticals may be limited to this
group.
In addition to glucosamine and chondroitin, other
nutraceutical products have been reported to provide
relief from OA [6-9]. Cat's claw extract has recently been
combined with a mineral based treatment (Sierrasil®) to
provide symptomatic relief for a group of mild to moder-
ate OA sufferers. While initially demonstrating some ben-
efit with the cats claw/mineral supplement, Miller and co-
workers observed that this benefit was at best temporary
for a 1–2 week period [10]. Even though the positive
effects were short lived in this subset of OA subjects, grow-
ing evidence suggests that minerals may play a role in
joint health.
Naturally occurring minerals such as magnesium, copper,
manganese, selenium and zinc have shown anti-inflam-
matory effects in both animal and human studies. In a rat
model of osteoarthritis, a deficiency of dietary magnesium
was demonstrated to enhance the amount of cartilage
damage [11]. Furthermore, increased magnesium in the
diet may influence inflammation through reducing the
serum level of the pro-inflammatory protein C-reactive
protein [12]. The trace element copper is an essential
cofactor in enzymes such as the collagen cross-linker lysyl
oxidase and the anti-oxidant enzyme super oxide dis-
mutase (SOD) that also requires zinc and manganese as
cofactors. Recent evidence has suggested a role for oxida-
tive stress in the pathogenesis of OA whereby an excess of
reactive oxygen species arising from an imbalance in the
antioxidant status of the joint (such as reduced levels of
SOD) may result in cartilage degradation and joint
remodeling [13]. Selenium is also an essential co-factor
for glutathione peroxidase may have a role in reducing the
incidence of osteoarthritic lesion [14,15] Positive roles
have also been suggested for trace minerals such as boron
and manganese in reducing the symptoms and slowing
the pathogenesis of OA [16].
The present study was designed to evaluate the potential
for a seaweed-derived multi-mineral supplement to allevi-
ate OA symptoms. The mineral supplement (Aquamin) is
derived from the red algae Lithothamnion corallioides
which is rich in calcium and magnesium and has a variety
of trace minerals (Table 1). The goal of this pilot trial was
to gain preliminary data regarding the impact of Aqua-
Table 1: Typical Mineral Composition of Aquamin
Mineral Dry Salt Weight
Calcium Carbonate 85% (34% calcium)
Magnesium Carbonate 8.5% (2.4% magnesium)
Salt (as chloride) 1.5%
Moisture 3.0%
Trace Minerals** 2.0%
Sulphur 0.7%
Potassium 0.6%
Phosphorus 0.05%
Sodium 0.25%
Manganese 100 ppm.
Zinc 20 ppm
Iron 800 ppm
Iodine 30 ppm
Boron 17 ppm.
Copper 8 ppm.
Cobalt 0.1 ppm.
Selenium 1.0 ppm.
**Aquamin contains a wide spectrum of trace minerals assimilated 
from sea water of which the minerals outlined in the remainder of the 
table are a selection.
Aquamin is a natural ingredient and trace mineral levels may vary over 
timeNutrition Journal 2008, 7:9 http://www.nutritionj.com/content/7/1/9
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min, Glucosamine Sulfate, the combination of Aquamin
and Glucosamine Sulfate, or Placebo on symptoms and
functional abilities of subjects with OA during 12 weeks
of treatment.
Materials and methods
Study design
This study was a randomized, double blind, placebo con-
trolled clinical trial with four parallel treatment groups:
Aquamin, Glucosamine Sulfate, Aquamin plus Glu-
cosamine Sulfate and Placebo. This trial was performed in
compliance with all applicable regulations and guidelines
(e.g. International Conference on Harmonization Good
Clinical Practices, ICH-GCP, the Declaration of Helsinki,
21CFR50-Protection of Human Subjects, and 21CRF56-
Institutional Review Boards) and was approved and con-
tinuously reviewed by the Quorum Institutional Review
Board (Seattle, WA).
Sample size
Since pretrial information about Aquamin was entirely
anecdotal, traditional effect sizes and sample size esti-
mates were not possible. We used our experience from a
previous study with similar endpoints to estimate the
number of subjects that might be needed for this pilot
trial. In our earlier trial, we found that 6 weeks of treat-
ment with glucosamine sulfate and/or hyper-immune
milk had a significant impact on WOMAC pain, stiffness
and activity scores among 35 OA subjects with 10–13 sub-
jects in each of the 3 treatment arms [6]. Based on this
information, we enrolled 15 subjects in each of the four
treatment arms (Aquamin, Glucosamine Sulfate, Aqua-
min plus Glucosamine Sulfate and Placebo) for a total of
70 subjects enrolled in this small pilot trial.
Subjects
This was a single centre study conducted at the Minnesota
Applied Research Centre and subjects were recruited by
advertising in the Minneapolis, Minnesota area. Subjects
of either gender were included if they voluntarily gave
informed consent, were ambulatory, 25–75 years old,
with normal digestion and absorption, diagnosed with
moderate to severe OA of the knee according to their pre-
vious medical history and the modified clinical criteria of
the American College of Rheumatology [17] and had a
Western Ontario and McMaster Universities (WOMAC)
Osteoarthritis Index [18] score ≤ 75 in the target knee. The
target knee was chosen by physical examination to iden-
tify the most severely effected knee for each subject and
the cut off point for the WOMAC score was enforced as a
means of standardizing the extent of pain and immobility
in the small number of subjects recruited for this trial. In
order to establish a standardized calcium intake across all
treatments, subjects were asked to consume a diet with
~600 mg calcium (e.g. two dairy servings) which was esti-
mated to be 40–60% of their RDI (depending on age) per
day.
Exclusion criteria were rheumatoid arthritis, gout, pseu-
dogout, Paget's disease, seizure disorder, insulin depend-
ent diabetes mellitus, uncontrolled hypertension,
unstable cardiovascular disease, active hepatic or renal
disease, active cancer and/or HIV infection or if they
required prescription drugs to control pain; had other
clinical trial or experimental treatments in the past 3
months; were pregnant, lactating, or at risk of becoming
pregnant; or if they received NSAIDS within 48 hours;
intramuscular/systemic corticosteroid injection within 4
weeks; intra-articular corticosteroid injection within 2
months; or inter-articular hyaluronic acid injection within
4 months prior to enrollment.
Each subject received one bottle of 350 two-piece hard
shell test article capsules each month. Each bottle (and the
capsules inside) appeared identical. Subjects were rand-
omized in blocks of 4 using sequential treatment assign-
ments prepared by the independent consulting
statistician. The clinical investigator, statistician, clinic
staff and subjects remained blinded throughout the trial
to avoid bias. The sequence of the study began with a two
week period when subjects were asked to discontinue any
prescription or over-the-counter or alternative therapy
treatments for osteoarthritis.
At the baseline visit, vital signs were assessed and labora-
tory tests were performed. Subjects were assessed for
WOMAC parameters and a 6 minute walking test was per-
formed. After each month of treatment (at 4, 8 and 12
weeks) the subject's diaries, WOMAC questionnaires, and
unused pills were collected, medications/supplements
were reviewed, adverse events investigated, vital signs
measured, blood was drawn and 6 MWD and WOMAC
were measured. Active treatment was completed at week
12 when laboratory tests were repeated. Each subject
returned to the clinic at 16, 20 and 24 weeks after their
treatment began for monitoring of blood chemistry only.
Although there was no reason to expect any beneficial
carry over effect on the OA symptoms after removal of the
treatments, subjects returned to the clinic every 4 weeks
for 12 weeks after termination for blood chemistry read-
ings in order to ensure that there were no adverse conse-
quences on their blood metabolites including their blood
calcium levels.
Treatments
The duration of treatment was 12 weeks, administered as
three capsules taken with a glass of water, three times per
day. The capsules contained Aquamin (267 mg Aquamin
F + 167 mg maltodextrin – FCC, USP & NF specifications
for 10 Dextrose Equivalent Maltodextrin which wasNutrition Journal 2008, 7:9 http://www.nutritionj.com/content/7/1/9
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assumed inert in the capsules) designated A in the results
section; Glucosamine sulfate (167 mg D-glucosamine sul-
fate Potassium salt, Pharmachem Labs NJ, USA + 267 mg
maltodextrin) designated GS, Aquamin and Glucosamine
(267 mg Aquamin F + 167 mg glucosamine sulfate) desig-
nated G+A, or Placebo (434 mg maltodextran) designated
PBO in the results section. The rescue medication was
acetaminophen, 325 mg, 1–2 tablets every 4–6 hours as
needed for intractable pain.
Study measurements and statistical analysis
Joint symptoms were assessed using the Western Ontario
and McMaster Universities (WOMAC) Osteoarthritis
Index, a validated questionnaire including scores for pain,
stiffness and activities as well as a composite (total) score.
The WOMAC scores were transformed according to the
standard orthopedic formula:
Transformed Score =
100 - (Actual Raw Score × 100/Possible Raw Score) [18]
The values represent "percentage of normal," such that
increasing scores reflect improvement and decreasing
scores reflect worsening of symptoms. The six minute
walking distance (6 MWD) was conducted by marking off
a 100-foot distance in an interior hallway and asking sub-
jects to walk as far as they can as quickly as they can over
6 minutes. The total distance was measured and recorded.
Adverse effects were assessed by a questionnaire and vital
signs/laboratory measurements respectively.
This study was conducted, monitored and audited in com-
pliance with ICH-GCP guidelines and according to the
Minnesota Applied Research Center Standard Operating
Procedures (SOP's) and the SOP's of certified vendors
(e.g. for WOMAC scoring). Subject compliance was
assessed at each visit by pill count, interview, and review
of the medication diary. Subject data was kept confiden-
tial and study records were stored in a locked and secure
storage area. An independent statistician used ANOVA for
between group comparisons at baseline. ANCOVA (with
baseline score as co-variate) were used to assess between-
group differences in change over time. Matched pair T-
tests were used for within group comparisons of change
over time. Data was analyzed under Intent To Treat Last
Observation Carried Forward (ITT-LOCF) case condition
and statistical significance was set at p < 0.05.
Results
Baseline characteristics
Table 2 shows that all four groups were comparable (on
average) for number of subjects (N = 15–20), gender (6–
11 male; 7–11 female), BMI (30.5 – 32.5), age (58.5 to
60.3 years), WOMAC activity (49.4–63.0) and composite
(48.8–63.4) scores and 6 MWD (1323–1427 feet) indicat-
ing that the randomization was effective for those param-
eters. Significant baseline differences were observed
between the four groups for WOMAC pain (50.0–67.2)
and stiffness scores (40.4–57.8) (p = 0.039 and 0.013
respectively). (Table 3) The finding of baseline differences
for the pain and stiffness sub-scores limits the analysis of
these data.
Subject attrition after release of the test article
Twenty (20) of the 70 subjects given test article withdrew
from the trial prior to completion (29% attrition) and a
total of 50 subjects completed the trial (Figure 1). The rea-
sons for subject attrition were spread evenly across the test
article administration groups and no pattern was obvious
that might suggest withdrawal due to a problem specific
to any of the test articles in this trial.
WOMAC
Using an ITT-LOCF analysis, only the improvements in
WOMAC pain score differed significantly between the
groups over the course of the study (p = 0.009 ANCOVA).
All four groups displayed numerical improvements from
baseline to end of treatment for WOMAC scores (Table 3
and Figure 2); however, no significant improvements
were demonstrated within groups over time for the pla-
cebo or for the combined treatment groups. Within group
analysis over time showed that the pain score was signifi-
cantly improved by 17.5 (P = 0.003 ANOVA) for A and
12.6 (P = 0.003 ANOVA) for GS compared to non signifi-
cant changes of 2.9 for PBO and 1.9 for G+A (higher score
indicates less pain).
Within group analysis over time showed that the activity
score was significantly improved by 13.6 (P = 0.010
Table 2: Baseline characteristics (ITT analysis).
Characteristic N started (completed) Gender M/F Mean age (S.D.) BMI (calc)
PBO 16(9) 6/10 58.9(7.4) 32.4
A 20(15) 11/9 58.5(12.1) 32.5
GS 19(14) 8/11 59.2(8.3) 32.1
G+A 15(12) 8/7 60.3 (9.8) 30.5
p (ANOVA*) NS NS NS NS
* = ANCOVA comparison between groupsNutrition Journal 2008, 7:9 http://www.nutritionj.com/content/7/1/9
Page 5 of 8
(page number not for citation purposes)
ANOVA) for A and 10.6 (P = 0.008 ANOVA) for GS com-
pared to non significant changes of 7.0 for PBO and 5.6
for G+A.
Within group analysis over time showed that the compos-
ite (total) WOMAC score was significantly improved by
14.9 (P = 0.006 ANOVA) for A and 10.8 (P = 0.007
ANOVA) for GS compared to non significant changes of
6.1 for PBO and 4.9 for G+A.
Of interest, the Aquamin group also displayed a signifi-
cant improvement over time for stiffness score (20.6, p =
0.002) compared to non significant changes of 10.5 for
GS, 5.9 for PBO and 6.3 for G+A.
Subject consumption of rescue medication
No significant differences were found between the groups
in the amount of rescue medication consumed over the
course of the experiment (Table 4).
Six minute walking distance (6 MWD)
The distance covered during a 6 minute timed walk was
significantly improved over time on treatment within the
Aquamin group (+101 feet, p = 0.001, Table 5). The glu-
cosamine group also demonstrated a significant improve-
ment in 6 MWD over time on treatment (+56 feet, p =
0.030). No significant improvements were demonstrated
within groups over time for the placebo group and sur-
prisingly for the combined treatment group.
Adverse effects
All treatments were well tolerated. Table 6 shows that a
total of 51 of the 70 subjects given test product (TA)
reported eighty-eight (88) adverse effects (AE) but only 7
of the 88 AE (8%) were considered at least possibly related
to the TA treatment. These AE were distributed somewhat
evenly across the groups: 1 on PBO, 3 on A, 2 on GS and
1 on G+A and none were considered definitely related to
the TA (Table 6). Most of the adverse effects (31/88; 35%)
were related to musculoskeletal complaints and these
were mainly reports of increased knee pain (n = 19/88;
22%). All AE completely resolved or returned to baseline.
Discussion
This trial was designed as a preliminary pilot trial to inves-
tigate the potential of a marine derived multi-mineral sup-
plement to reduce symptoms of moderate to severe knee
osteoarthritis. The dose of the mineral supplement Aqua-
min was determined based on previous anecdotal experi-
ence and a rigorous Intent to Treat – Last Observation
Carried Forward statistical analysis was used to compare
the four treatment groups: Aquamin, Glucosamine Sul-
fate, Combination of Aquamin and Glucosamine Sulfate,
or placebo.
These results were confounded because the WOMAC pain
scores were significantly different between the groups at
baseline and, therefore, these improvements need to be
viewed with caution because further study is warranted. In
general, significant differences were found between
groups for pain scores after 12 weeks of treatment. Within
groups over time, the Aquamin treatment group showed
significantly improved WOMAC pain, stiffness, activity
and composite scores over the course of the 12-week treat-
ment. The glucosamine sulfate treatment group also
showed significant improvements over time on treatment
for the pain, activities and composite scores (but not for
the stiffness scores); however, no significant improve-
Table 3: Changes in WOMAC Scores at baseline and at the end of the trial Between and Within Groups (ITT-LOCF)
Variable Pain
Baseline
Pain
End
Pain 
baseline 
– pain 
end
Stiffness
Baseline
Stiffness
End
Stiffness 
baseline 
– 
stiffness 
end
Activity
Baseline
Activity
End
Activity 
baseline 
– activity 
end
Composite
Baseline
Composite
End
Composite 
baseline – 
composite 
end
PBO 50.0 52.9 -2.9 40.4 46.3 -5.9 49.4 56.4 -7.0 48.8 54.8 -6.1
SD 22.9 21.4 19.9 17.4 25.3 18.3 23.1 24 18.4 21.8 22.7 17.6
Sig.* NS NS NS NS
A 56.8 74.3 -17.5 44.4 65 -20.6 58.8 72.4 -13.5 57.3 72.2 -14.9
SD 15.8 17.6 22.7 17 17.5 26.1 16.2 16.8 21.3 15.3 16.6 21.4
Sig.* .0.003 0.002 0.01 0.006
GS 60.6 72.9 -12.6 51.3 61.8 -10.5 60.1 70.7 -10.6 59.4 70.2 -10.9
SD 14.8 17.6 16.3 13.8 19.8 24.0 13.9 18.4 15.4 13.2 17.6 15.6
Sig.* 0.003 NS 0.008 0.007
G+A 67.2 69.1 -1.9 57.8 64.1 -6.3 63 68.6 -5.6 63.4 68.3 -4.9
SD 13.3 16.9 14.0 15.7 17.6 17.7 8.7 13.1 11.0 8.1 12.9 101
Sig.* NS NS NS NS
p(ANCOVA) 0.039# 0.009 0.013# NS NS# NS NS# NS
*Sig. = significance by within group paired t-test; 2-tailed; ANCOVA comparison between groups with baseline measure as covariate.
# = ANCOVA comparison between groups showing any differences at baseline for these parameters.Nutrition Journal 2008, 7:9 http://www.nutritionj.com/content/7/1/9
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Percent change in WOMAC scores from baseline over 12  weeks of treatment Figure 2
Percent change in WOMAC scores from baseline 
over 12 weeks of treatment.
Table 4: Consumption of rescue medication.
Group Month 1 Month 2 Month 3 Total
Placebo 39(38)* 27(27) 30(33) 89(88)
A 45(62) 19(22) 23(31) 87(96)
GS 25(20) 29(38) 31(50) 84(103)
G+A 26(55) 26(34) 27(46) 63(112)
*Mean (SD). Group comparisons of rescue medication were non-
significant (Kruskal-Wallis one-way non-parametric analysis of 
variance) at all time periods and for total medications
Trial flow chart Figure 1
Trial flow chart.Nutrition Journal 2008, 7:9 http://www.nutritionj.com/content/7/1/9
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ments were found over time on treatment for subjects in
the Placebo group or, surprisingly for subjects in the Com-
bination treatment group.
No baseline differences were observed among the four
groups for the 6 minute walking distances. Over time on
treatment, the Aquamin and glucosamine groups demon-
strated significant improvements in 6 minute walking dis-
tances (101 feet, p = 0.001 and 56 feet, p = 0.030,
respectively). This was an improvement of 7% and 3.5%
respectively over their baseline walking distances. No sig-
nificant differences were found for the walking distances
measured for the placebo group and surprisingly for the
combined treatment group. Although, these distances
appear to be small, our subjects with severe OA indicated
that the ability to walk even a little bit further was impor-
tant to them.
The main limitations of this study were its short duration
(12 weeks), lack of assessment for remnant effects after
treatment stopped and limited sample size (15 subjects
per treatment arm). Glucosamine sulfate has been shown
to provide a benefit over a longer course of treatment [4]
and its efficacy may have been under demonstrated within
this 12 week study period. Additional study of longer
treatments in a greater numbers of subjects would be
helpful to verify the treatment effect for Aquamin and to
explore the lack of any treatment effect for the combina-
tion of Aquamin and Glucosamine Sulfate in this small
pilot trial. Although these products are unlikely to have
reacted in the tablet form it is interesting to speculate
about a possible dietary interaction, possibly related to
the very basic nature of Aquamin (pH 10) compared to
the acidity of the Glucosamine Sulphate (pH of 3.5 to 5),
and the requirement for this to ionize in the stomach to
be effective.
Aquamin is composed of multiple minerals and the
'active ingredient' for the complex is difficult to deter-
mine. A number of the minerals in Aquamin may have
anti-inflammatory and anti-oxidant properties which
might directly and/or indirectly influence the efficacy of
Table 5: Changes in 6 MWD Between and Within Groups Over 12 weeks of treatment.
Variable Baseline 6 MWD End 6 MWD Baseline-End 6 MWD
PBO 1323.4 1331.9 -8.4
SD 226.1 250.2 109.3
Sig.* NS
A 1427.5 1528.8 -101.3
SD 225.6 252.3 121.5
Sig.* 0.001
GS 1410.1 1456.8 -55.7
SD 246.1 256.1 103
Sig.* 0.03
G+A 1363.1 1378.1 -15
SD 253.7 253 126.6
Sig.* NS
p (ANCOVA) NS
*Sig. = significance by within group paired t-test; 2-tailed; ANCOVA comparison between groups with baseline measure as covariate
Table 6: Adverse effects
Item Total GS A PBO G+A
Number of Subjects with AE 51 12 12 14 13
HEENT 25 6 8 6 5
Respiratory/Pneumonia 10 0 0 1
Cardiovasular/Hypertension 10 0 0 1
Gastrointestinal 17 5 3 6 3
GU/Reproduction 31 1 0 1
Neurological 51 3 1 0
Dermatological (hives, cat bite) 21 0 0 1
Musculoskeletal 31 4 9 10 8
Increased Knee Pain 19 4 5 4 6
Other 61 1 0 4
TOTAL 88 18 25 23 22Nutrition Journal 2008, 7:9 http://www.nutritionj.com/content/7/1/9
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this unique complex [13,14,16]. While the prominent
mineral present in Aquamin is calcium (dosage = 80% Ca
U.S RDA), its role in joint health is unclear. Magnesium
however, was given at the daily dosage providing 14%
(male) to 18% (female) U.S. RDA [12] and over the
course of this study, this increased consumption of mag-
nesium may have influenced OA symptoms by affecting
the utilization of calcium or by potentially reducing
inflammation around the affected joint. Both manganese
and selenium were given at the daily dosage providing up
to 16% and 4% of their RDA respectfully. Both of these
trace minerals have been reported to reduce the appear-
ance of osteoarthritic lesions and reduce the severity of
symptoms in OA [14,16].
These pilot trial results suggest a potential treatment effect
for Aquamin among subjects with moderate to severe OA
and this preliminary finding warrants further study.
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